HJ-004-02
/ Jing Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 31, 2026
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Mutations
(ChiCTR)
- P1 | N=36 | Not yet recruiting | Sponsor: Shanghai East Hospital; Jing Medicine Technology (Shanghai) Co., Ltd.
New P1 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
January 23, 2026
HJ-004-02-101: A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Tongji University
New P1 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR
1 to 2
Of
2
Go to page
1